News 01.09.2020 Schlieren (Zurich), Switzerland, September 1, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease. The first patient was...
News 26.08.2020 Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial in vitro and in vivo data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen. Secured partnership with AGC Biologics to meet initial projected...
News 14.08.2020 Swiss biotech company Memo Therapeutics AG (MTx) isolated a highly potent antibody isolated from clinically selected convalescent COVID-19 donors. The selected antibody will undergo an accelerated development program as an immunotherapy and for the prevention of COVID-19. MTx has already concluded a partnership for the production. MTx today announces a collaboration...
News 12.08.2020 Schlieren (Zurich), Switzerland, August 12, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2020. Despite the adverse impact of COVID-19 on elective surgery, Kuros accelerated sales of its lead product MagnetOs, which increased by 42% compared to...
Events, Internal events
Event date: 19.08.2020
This webinar occurs several times. Please register for the date and time that works best for you.
Register now!
Biopharmaceuticals can save lives if the product quality is guaranteed. The Quality by Design (QbD) concept ensures that such quality is built into the process and its products from the very start of...